Dose the first patient in the BEAM-201 trial

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 9 Jan 2023
Due: 30 Jun 2023
Delivered: August 2023

Deadline
Met
Late
Not met
Today

What the company said

“Dose first BEAM-201 patient by mid 2023”

SourceBeam Therapeutics Inc. Form 8-K press release, 2023-01-09
FilingSEC filing index
Deadline as statedby mid 2023
Deadline used30 Jun 2023, the last day of the stated period
TypeProject
Permanent referenceKI-C-2023-BEAM-003226
Cite as https://keptindex.org/c/KI-C-2023-BEAM-003226/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company committed to dosing the first BEAM-201 patient by mid-2023, but the first patient was not dosed until August 2023.

A
Beam Therapeutics Inc. 10-Q filed 2023-11-08 Regulatory filing · published 8 Nov 2023 · retrieved 2 Oct 2026 · kept permanently by the SEC
“the first BEAM-201 trial patient was dosed in August 2023.” ✓ confirmed on the page

Market reaction: the shares moved -12.2% against the S&P 500 over the three sessions around the disclosure (7 Nov 2023 to 10 Nov 2023). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

1 versions

Version 1 · original · stated 9 Jan 2023

Deadline 30 Jun 2023 (“by mid 2023”)
Version 2 · stated 8 Aug 2023

Deadline 30 Sep 2023 (“the third quarter of 2023”) · wording expected

“The first patient has consented and is expected to be dosed in the third quarter of 2023.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Dose
Deliverable: First BEAM-201 patient dose
In the company’s control: High
Specificity: High
Depends on: Customer

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.